bioAffinity Technologies announced record monthly unit sales for CyPath® Lung in April 2026, up nearly 300% from April 2025, signaling accelerating adoption of its noninvasive lung cancer diagnostic test.
Key takeaways
CyPath® Lung unit sales hit record high in April 2026, based on preliminary unaudited data.
Unit sales increased nearly 300% in April 2026 vs. April 2025.
Growth exceeds internal projections and reflects accelerating physician adoption.
Test aids lung cancer risk stratification and pulmonary nodule management.
Company prioritizing CyPath® Lung commercialization with expanded physician sites and education.